| Document |
Document Title |
|
WO/2020/224585A1 |
Disclosed are a salt and a crystal form of an mTORC1/2 dual kinase inhibitor and a preparation method therefor. Also disclosed is use of the salt and crystal form in the preparation of a medicament related to the mTORC1/2 dual kinase inh...
|
|
WO/2020/221006A1 |
The present invention relates to the technical field of biomedicine, and specifically relates to a BET inhibitor, and a preparation method and use thereof. The present invention improves on the structure of prior art BET inhibitors to ob...
|
|
WO/2020/216350A1 |
Provided are quinoline derivative compounds of formulae (I), (II) and (III) with an inhibitory effect on mTOR and applications of their pharmaceutically acceptable salts, their stereoisomers, their hydrates or their solvates in preparati...
|
|
WO/2020/211140A1 |
Provided in embodiments of the present application are an electroluminescent material, a preparation method for an electroluminescent material, and a light-emitting device; an electroluminescent material is generated by means of reacting...
|
|
WO/2020/207941A1 |
The application relates to heterocyclic compounds of the general formula (I), compositions comprising such compounds, a process for preparing these compounds and their medical use. The compounds act as monoacylglycerol lipase (MAGL) inhi...
|
|
WO/2020/207991A1 |
The present invention relates to compounds of formula (I), wherein R1 to R3, n and A are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.
|
|
WO/2020/209205A1 |
The present invention addresses the problem of providing a compound having high photobase generation efficiency. This carbamoyloxime compound is represented by general formula (I) (in the formula, A represents an aromatic ring-containing...
|
|
WO/2020/204402A1 |
The present invention provides: a compound represented by chemical formula 1; an organic electric element comprising a first electrode, a second electrode, and an organic layer placed between the first electrode and the second electrode;...
|
|
WO/2020/201773A1 |
The present invention relates to compounds of formula (I) that function as inhibitors of METTL3 (N6-adenosine-methyltransferase 70 kDa subunit) enzyme activity: X-Y-Z5 (I) wherein X, Y and Z are each as defined herein. The present invent...
|
|
WO/2020/203950A1 |
The present invention provides: a novel compound having a CSF-1R inhibitory activity and an antineoplastic effect; a salt thereof; or a solvate of these. An azaindole derivative represented by general formula (I) (in the formula, A rep...
|
|
WO/2020/200154A1 |
The present invention discloses a thiophene fused N-heterocycle represented by formula I, or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, polymorph or prodrug thereof, the preparation method thereof an...
|
|
WO/2020/201991A1 |
Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases. Methods of using compounds of Formula I or a stereoi...
|
|
WO/2020/206381A1 |
The present application provides novel cephem, penem, and monobactam compounds that exhibit antibiotic activity against both Gram-negative and Gram-positive bacteria, as well as compositions comprising these compounds and methods of usin...
|
|
WO/2020/201096A1 |
The present invention provides novel compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds of formula (I) can act as CXCR4 modulators that specifically target the CXCR4 minor pocket, and they ...
|
|
WO/2020/203763A1 |
The present invention provides: a compound represented by Formula (I) [wherein Q is a group or the like represented by Q1, Z represents an oxygen atom or the like, A1 represents CR4a or the like, A2 represents a nitrogen atom or the like...
|
|
WO/2020/205564A1 |
The invention relates to benzodiazepine derivatives with antiproliferative activity and more specifically to benzodiazepine compounds of formulae (I), (II), (TI) and (T2). The invention also provides conjugates of the benzodiazepine comp...
|
|
WO/2020/205683A1 |
In immunoglobulin light chain amyloidosis (AL), the unique antibody light chain (LC) protein that is secreted by monoclonal plasma cells in each patient misfolds and/or aggregates, a process leading to organ degeneration. For treating AL...
|
|
WO/2020/196828A1 |
This nitrogen-containing heterocyclic compound can have an NMDA receptor antagonistic effect and is expected to be useful as a preventive or therapeutic agent for depression (including severe depression, refractory severe depression, and...
|
|
WO/2020/192762A1 |
Provided are a salt form and a crystal form of adenosine A2A receptor antagonist, and preparation method therefor. Also provided is an application of the salt form or crystal form in the preparation of a medicine for A2A receptor-related...
|
|
WO/2020/198323A1 |
The present disclosure describes compounds of formulas (I)-(V) and methods of making the same. The compounds of the present disclosure are useful as inhibitors of PRMT5 activity and in methods of treating cancers and other diseases.
|
|
WO/2020/194237A1 |
Methods of rapidly inhibiting efflux from a cell, sensitizing a drug-resistant cell to a drug and treating a subject with a drug-resistant pathology, by administering tetrahydrocannabinolic acid (THCa), cannabidiol (CBD) or a combination...
|
|
WO/2020/193447A1 |
The invention relates to compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing said compounds.
|
|
WO/2020/189283A1 |
An objective of the present invention is to provide a charge-transporting compound that suppresses changes in physical properties of a charge-transfer/light-emitting thin film over energization time and that is excellent in light emissio...
|
|
WO/2020/189236A1 |
An organic film according to the present invention contains a charge-transport material having a structure represented by general formula (1). [In general formula (1), n represents an integer of 4-6 and m represents an integer of 0-2, pr...
|
|
WO/2020/187721A1 |
A compound of formula IV: as well as drug-linkers and conjugates comprising this compound, and the use of the conjugates in treating cancer.
|
|
WO/2020/182062A1 |
The present invention relates to an FGFR4 kinase inhibitor, a preparation method therefor and use thereof. The present invention relates to a compound of formula I, or a pharmaceutically acceptable salt, solvate, polymorph or isomer ther...
|
|
WO/2020/184369A1 |
The purpose of the present invention is to provide a red-light-emitting material having high light emission efficiency and excellent color purity and a red-light-emitting element. This invention is a pyrromethene metal complex represente...
|
|
WO/2020/180907A1 |
Compounds having the following formula I: or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein all substituents are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα by acting on Tyk-2 to ca...
|
|
WO/2020/178796A1 |
Benzodithiophene conjugated polymer of general formula (I): wherein: R1 and R2, mutually identical or different, are selected from linear or branched, saturated or unsaturated, preferably C2-C20, C1-C30 alkyl groups; optionally substitut...
|
|
WO/2020/177678A1 |
Disclosed is a use of a multi-target tyrosine kinase inhibitor in combination with an EGFR inhibitor in preparing a drug for treating a tumor. In particular, the multi-target tyrosine kinase inhibitor described in the present application...
|
|
WO/2020/173902A1 |
A method of synthesising a compound of formula (I) from a compound of formula (II) wherein R2 is phenyl, substituted at either the meta- or para-position by the group (III) where Q is an amino acid residue (-C(=O)-X1-NH-), a di-amino aci...
|
|
WO/2020/176424A1 |
The present disclosure relates generally to compounds that simultaneously bind both mutant huntingtin protein (mHTT) and an ubiquitin E3 ligase and their use as therapeutic agents, for example, in treating diseases, such as neurodegenera...
|
|
WO/2020/171077A1 |
The present invention provides: a compound that exhibits an excellent harmful arthropod-controlling effect and is represented by formula (I) [in the formula, Q represents a group represented by Q1 or a group represented by Q2, Z represen...
|
|
WO/2019/196950A9 |
The present invention discloses a compound taking xanthone as a core, a preparation method thereof and an application thereof in OLED. The compound contains a xanthone structure, and at least one N exists in a five-membered ring branched...
|
|
WO/2020/166680A1 |
The present invention provides a novel compound inhibiting EGFR or a salt of the compound. According to one embodiment of the present invention, provided is a compound represented by general formula (I) or a pharmaceutically acceptable s...
|
|
WO/2020/156357A1 |
The present invention relates to a compound having a benzo seven-membered ring structure, a preparation method therefor, and use thereof. The compound has a structure as represented by formula (I). Provided is use of the compound having ...
|
|
WO/2020/156271A1 |
A 7-azaindole derivative having the structure of formula (I), a pharmaceutical composition containing the compound of formula (I), and uses of the compound in preparing a medicament for preventing or treating Janus kinase (JAK) family-re...
|
|
WO/2020/158889A1 |
The present invention provides a compound having an excellent control effect against harmful arthropods. A compound represented by formula (I) [wherein Q represents a group represented by Q1 or a group represented by Q2; Z represents an ...
|
|
WO/2020/156437A1 |
The present invention discloses an AKT inhibitor, and specifically relates to a compound represented by formula I or a pharmaceutically acceptable salt thereof. The present invention further provides a preparation method thereof, and the...
|
|
WO/2020/152132A1 |
The invention relates to thiazolopyridine derivatives which fall under the general formula I, (I) and the use of the compounds of the present invention for the treatment and/or prevention of hyperproliferative or infectious diseases and ...
|
|
WO/2020/151499A1 |
Disclosed are a fluorene derivative and an electronic device. Fluorene rigid structure, fluorene derivative film forming ability and thermal stability make the fluorene derivative disclosed herein an excellent candidate for preparing an ...
|
|
WO/2020/151543A1 |
Disclosed are a thermally activated delayed fluorescence compound, a light emitting material and an OLED device. The thermally activated delayed fluorescence compound in the present disclosure is represented by the following general form...
|
|
WO/2020/150626A1 |
This invention relates to Imidazo[1,2-a]pyridinyl Derivatives of formula (I'), or pharmaceutically acceptable salts thereof, in which all of the variables are as defined in the specification, capable of modulating the activity of IRAK4. ...
|
|
WO/2020/145250A1 |
[Problem] To provide a compound having a 15-PGDH inhibitory effect. [Solution] A compound represented by general formula (1) or a pharmacologically acceptable salt thereof.
|
|
WO/2020/146237A1 |
The present application provides heteroaryl amide compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer.
|
|
WO/2020/141135A1 |
Compounds of the formula (I), wherein the substituents are as defined in claim 1. Furthermore, the present invention relates to agrochemical compositions which comprise compounds of formula (I), to preparation of these compositions, and ...
|
|
WO/2020/135686A1 |
Disclosed by the present invention are an organic compound with a carbazole derivative as the core and a preparation method therefor and an application thereof, which relate to the technical field of semiconductors. The structure of the ...
|
|
WO/2020/127624A1 |
The present invention relates to novel compounds of formula (I), wherein R1 to R7 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and metho...
|
|
WO/2020/131629A1 |
The present invention provides compounds of formula (I): which are useful in the control of endoparasites, for example heartworms, in warm-blooded animals.
|
|
WO/2020/132071A1 |
Provided herein are methods and compositions for treating cancers, inflammatory diseases, rasopathies, and fibrotic disease involving aberrant Ras superfamily signaling through the binding of compounds to the GTP binding domain of Ras su...
|
